<DOC>
	<DOCNO>NCT03000257</DOCNO>
	<brief_summary>This open-label , Phase I , dose-escalation study determine recommend Phase 2 dose ( RPTD ) , maximum tolerate dose ( MTD ) , evaluate safety pharmacokinetic ( PK ) profile ABBV-181 . The study consist 2 part : ABBV-181 dose escalation ABBV-181 dose expansion .</brief_summary>
	<brief_title>A Study ABBV-181 Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Participant must advance solid tumor must candidate surgical resection approve therapeutic regimen know provide clinical benefit . For dose escalation , participant may previously treat program cell death 1 ( PDI ) target agent . For dose expansion , participant must PDI/PDL1 target agent na√Øve . Participant Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . Participants adequate bone marrow , renal , hepatic coagulation function . Participants must measurable evaluable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 dose escalation portion trial . Participants expansion cohort must measurable disease per RECIST version 1.1 disease evaluable assessment tumor antigen . Participant receive anticancer therapy include chemotherapy , immunotherapy , radiation therapy , biologic , herbal therapy , investigational therapy within period 21 day , prior first dose ABBV181 . Participant unresolved adverse event great equal grade 1 prior anticancer therapy except alopecia . Current prior use immunosuppressive medication within 14 day prior first dose ( certain exception ) . History primary immunodeficiency , bone marrow transplantation , chronic lymphocytic leukemia , solid organ transplantation , previous clinical diagnosis tuberculosis . Confirmed positive test result human immunodeficiency virus ( HIV ) , participant chronic active hepatitis B C. Participant know history inflammatory bowel disease , pneumonitis , know uncontrolled metastasis central nervous system ( CNS ) ( certain exception ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Merkel cell carcinoma</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Small cell lung cancer</keyword>
	<keyword>Mesothelioma ,</keyword>
	<keyword>Cancer</keyword>
</DOC>